FDA Approves Coagadex for Rare Clotting Disorder

Share this content:
FDA Approves Coagadex for Rare Clotting Disorder
FDA Approves Coagadex for Rare Clotting Disorder

WEDNESDAY, Oct. 21, 2015 (HealthDay News) -- Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor X deficiency.

Coagadex, derived from human blood plasma, has been approved for people 12 years and older to control and prevent random bleeding episodes, and those stemming from menstruation or recent surgery.

The product was evaluated in clinical studies of 16 patients with moderate to severe hereditary Factor X deficiency, and demonstrated efficacy in controlling bleeding episodes. No safety concerns were identified in these studies, the FDA said.

"The approval of Coagadex is a significant advancement for patients who suffer from this rare but serious disease," Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

Coagadex is manufactured by Bio Products Laboratory Ltd., based in the United Kingdom.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC Concerned About Falling Flu Vaccination Rates

CDC Concerned About Falling Flu Vaccination Rates

Decline among vulnerable older adults is of particular concern

One in Five With Non-Valvular A-Fib Receiving Digoxin

One in Five With Non-Valvular A-Fib Receiving Digoxin

Indication for digoxin use was considered inappropriate in 59.8 percent in Turkish cohort

Rapid, Successful Response to ART for Many Patients With HIV

Rapid, Successful Response to ART for Many Patients ...

Factors associated with virological success include having undetectable viral load, use of three drugs

is free, fast, and customized just for you!

Already a member?

Sign In Now »